UK trial reports 4-year event-free survival of 63% and overall survival of 68% in relapsed Wilms tumour patients
High-dose chemo plus stem cell rescue offers hope for relapsed Wilms tumour
This clinical trial report evaluates outcomes for 78 children with relapsed or refractory Wilms tumour treated in the United Kingdom.
A UK trial found that a risk-stratified protocol with high-dose melphalan and stem cell rescue helped some children with relapsed Wilms tumo…
Autologous hematopoietic stem cell transplantation improves disease-free survival in pediatric extraocular retinoblastoma patients
Children With Eye Cancer Now Have a New Hope for Survival
This retrospective analysis included 12 children with extraocular retinoblastoma treated with autologous hematopoietic stem cell transplanta…
Children with advanced eye cancer can now achieve long-term survival using their own stem cells, especially if the disease has not reached t…
Itacitinib plus standard therapy in acute leukemia or myelofibrosis patients undergoing reduced-intensity conditioning donor stem cell transplantation
Early trial explores itacitinib for stem cell transplant patients with blood disorders
This Phase IIa trial evaluated itacitinib combined with tacrolimus and sirolimus in patients with acute leukemia, myelodysplastic syndrome, …
A new trial adds itacitinib to standard care for stem cell transplant patients with blood disorders to help prevent graft-versus-host diseas…
Early daratumumab or immunomodulatory agents in high-risk smoldering multiple myeloma show uncertain benefits versus observation
Early Drug May Delay Multiple Myeloma
This systematic review evaluated early intervention with monoclonal antibodies, immunomodulatory agents, or alkylating agents versus observa…
Imagine waking up with a headache. You take a pill, and the pain goes away.
SVRD yields 89.7% ORR, 79.3% EMD resolution in NDMM with EMD in phase 2 trial
Can a new drug combination help people with aggressive multiple myeloma? Early results show promise
In a phase 2 trial of 29 patients with newly diagnosed multiple myeloma and extramedullary disease (EMD), selinexor combined with VRD (SVRD)…
A new four-drug combination helped nearly 90% of patients with aggressive multiple myeloma shrink or eliminate cancer outside the bone marro…